CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 436 enrolled
Drug / intervention
Vitamin D +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01748448
NCT01748448Phase 3Completed
CompareCT.gov

Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome

Universitaire Ziekenhuizen KU Leuven·interventional·Posted Dec 12, 2012·Updated Feb 17, 2025

In Brief

A Phase 3 clinical trial evaluating Vitamin D and Placebo: Oil for Cutaneous Malignant Melanoma. Completed, enrolled 436 participants across 4 sites in 2 countries.

Detailed Summary

To assess whether vitamin D supplementation after surgery of a first cutaneous malignant melanoma protects against relapse of the disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Malignant Melanoma
CountriesBelgium, Hungary
CollaboratorsKU Leuven

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 12, 2012
Enrollment StartDec 1, 2012
Primary CompletionJul 1, 2022
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 13.6 years ago

Interventions

Vitamin Ddrug

* prospective interventional randomized double blind placebo controlled trail * clinical setting (tertiary university hospital) * investigator driven, no pharmaceutical sponsor * cutaneous malignant melanoma patients * add- on study (placebo or vitamin D) on top of optimal standard care * 1:1 inclusion ratio (placebo:Vitamin D) * randomisation after informed consent and screening

Placebo: Oildrug